ClinicalTrials.gg
CompletedNCT05779605Tele@homeUpdated Sep 30, 2026

Telerehabilitation in Hemato-oncological Survivors

An interventional study of Home-based training and Center-based training in Hematologic Malignancy and Lymphoma, sponsored by Brno University Hospital. Completed at 1 site in Czechia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-30.

Sponsored by Brno University Hospital · Not applicable, Interventional, and Supportive care

How we know

Updated Sep 30, 2026Now CompletedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 15 studies in Hematologic Neoplasms with a site in Czechia — 7 open to participants now, 8 under way, 3 of them phase 3. Hematologic Neoplasms · Czechia.

Enrollment
9th of 14
80 · median 183
Started
2023
with 1 other
No phase
Only one
of the 15
Registered
12th of 15
by date
Lead sponsor
1 of 15
Brno University Hospital

Among the 15 studies in Hematologic Neoplasms with a site in Czechia, this one is the 9th largest by enrollment of the 14 interventional ones that give a count, is one of 2 that started in 2023, is the only one with no phase, and was the 12th registered.

Hematologic Neoplasms

1,449 studies on the registry are indexed under Hematologic Neoplasms; 422 are open to participants now.

Browse Hematologic Neoplasms studies →

Open to participants now

7 of the 15 studies in Hematologic Neoplasms with a site in Czechia are open now. Recruiting first, the newest first:

2 more — sign in →

All 7 open studies →

A study can be open while its sites in Czechia have not opened yet or have stopped. Only those recruiting at a site in Czechia →

Who these studies take

Of the 313 Hematologic Neoplasms studies recruiting now, 209 (67%) set no upper age limit and 78 (25%) stop at 75 or younger; 81 take children under 18; 34 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Hematologic Neoplasms with a site in Czechia, or all of them as a file.
02

Study summary

This study investigates whether the 12-week home-based exercise training with remote guidance and telemonitoring compared to regular center-based training leads to better long-term cardiorespiratory fitness and physical activity levels in post-treatment patients with lymphoma.

Read the detailed description

80 lymphoma cancer patients post-treatment (except adjuvant treatment) will be enrolled in the study. Cardiorespiratory fitness (peak oxygen consumption), adverse events, body composition, quality of life, costs and adherence to exercise prescription will be evaluated at baseline, 12-week, and year after enrollment.

Investigators assume that home-based training with remote guidance and telemonitoring with objective training data obtained during rehabilitation after cancer treatment will improve long-term motivation and effectiveness of independent training in cancer survivors, resulting in superior cardiorespiratory fitness and physical activity levels.

03

Conditions studied

  • Hematologic Malignancy
  • Lymphoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria: Participants

  • with hemato-oncological / lymphoma (in last two months)
  • after cancer systemic chemotherapy-based treatment
  • with clinically stable state
  • with the ability to perform a cardiopulmonary exercise test
  • with the ability to understand and write in the Czech language
  • with an internet connection at home
  • literacy with information and communication technology

Exclusion Criteria: Participants

  • with acute heart disease or decompensation in the previous six weeks,
  • with psychological severe, cognitive disorders,
  • serious training limitations (musculoskeletal disorders)
  • currently carried out the recommendations for physical activity (150min per week)
  • who take part in a training program under supervision elsewhere
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
80 participants (actual)

Study arms

  • Experimental
    Home-based training

    12 weeks of home-based exercise training using modern technology to transfer exercise data remotely. The participants receive a heart rate monitor and sensor. Three sessions per week will be performed (36 sessions overall).

    Device: Home-based training

  • Active comparator
    Center-based training

    12 weeks of centre-based exercise training under supervision physiotherapists specializing in exercise rehabilitation. The participants receive a heart rate monitor and sensor. The patients in the Center-based training group receive an individually tailored training program on a treadmill and a bicycle ergometer. Three sessions per week will be performed (36 sessions overall).

    Device: Center-based training

Interventions

  • DeviceHome-based training

    Patients will be instructed to perform three weekly training sessions at home (30 to 50 min/session, at an intensity of 70-85% of their maximum heart rate). Patients in the home training group complete the first three training sessions in the clinic under direct supervision. During these sessions, patients are introduced to the duration and intensity of training. The trainer will provide remote guidance (feedback on training frequency, duration, and intensity) via telephone call once a week. During exercise, patients will use a wearable heart rate monitor (Polar M430, a commercially available device designed for long-term use). Patients will be instructed to properly use the wearable sensor and upload training data to a web-based platform (Polar Flow) via the Internet. Furthermore, patients will be asked to choose their preferred training modality at home (cycling, walking, Nordic walking) and receive instructions and advice.

  • DeviceCenter-based training

    Patients receive three training sessions a week with 30 to 50 min duration at 70 - 90% of their maximal heart rate at the outpatient clinic under direct supervision. Exercise modalities will be walking on a treadmill, riding a bicycle ergometer, and resistance training. Physiotherapists will track the attendance rate and training adherence during the training program.

06

What researchers measure

Primary outcomes

  1. Cardiorespiratory fitness

    Peak oxygen uptake during cardiopulmonary exercise test

    Time frame: Change from baseline to 12 weeks and 52 weeks

Secondary outcomes

  1. Health-related quality of life

    Health-related quality of life (SF-36 Form) yields a score for each domain of health. All domains are scored on a scale from 0 (negative health) to 100 (positive health), with 100 representing the best possible health state

    Time frame: Change from baseline to 12 weeks and 52 weeks

  2. Satisfaction - self-completed questionnaire

    Subjects will be provided with a 5-item self-completed questionnaire developed by our research team that will measure their satisfaction with the intervention they received and the study in general. The items will be presented in the form of statements to which subjects will be asked to respond using a 1-5 Likert scale ("strongly agree", "agree", "not sure", "disagree", and strongly disagree").

    Time frame: 12 weeks and 52 weeks

  3. Body water

    Total body water in liters will be measured by bioelectrical impedance analysis.

    Time frame: Change from baseline to 12 weeks and 52 weeks

  4. Muscle mass

    Total muscle mass in kilograms will be measured by bioelectrical impedance analysis.

    Time frame: Change from baseline to 12 weeks and 52 weeks

  5. Body fat percentage

    Body fat percentage will be measured by bioelectrical impedance analysis.

    Time frame: Change from baseline to 12 weeks and 52 weeks

  6. Incidence of exercise adverse events assessed by 5 grade scale

    Participants will be encouraged to use the contact details for reporting incidence of exercise adverse events at any time throughout the study period. The type, incidence, and severity of adverse events by scale (Grade 1: Mild, asymptomatic or mild symptoms; Grade 2: Moderate, minimal; Grade 3: Severe or medically significant; Grade 4: Life-threatening consequences; and Grade 5: Death) will be noted.

    Time frame: Data will be recorded continuously from the intervention's baseline for 12 weeks and then for 52 weeks

  7. Training adherence (Number of compliant participants)

    Evaluation of the total number of compliant participants (The criterium of compliance with the rehabilitation program is set at 70% of the prescribed training lessons, 100% = 36 lessons)

    Time frame: 12 weeks

  8. Maximum Grip Strength

    Maximum grip strength during dynamometer evaluation

    Time frame: Change from baseline to 12 weeks and 52 weeks

07

Study locations

1 site
  • University Hospital Brno
    Brno, Czechia
08

References and documents

Publications

  • Chamradova K, Batalik L, Winnige P, Dosbaba F, Hartman M, Batalikova K, Janikova A, Nehyba S, Felsoci M, Pepera G, Su JJ. Effects of home-based exercise with telehealth guidance in lymphoma cancer survivors entering cardio-oncology rehabilitation: rationale and design of the tele@home study. Cardiooncology. 2024 Jul 30;10(1):46. doi: 10.1186/s40959-024-00249-7. PubMed 39080734 ↗
09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2023 to primary completion in Sep 2026, 41 months.

Of 186 non-industry interventional studies with no phase under Hematologic Neoplasms, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 125. This study's 41 months is close to that.

Counting every sponsor, half of 192 studies reached it within 40 months; a quarter within 21 and three quarters within 82.

Since we started tracking on Sep 25, 2026, the dates moved once, on Sep 30, 2026: primary completion Dec 2025 → Sep 2026 and completion Dec 2026 → Sep 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 8, 2023
First posted
Mar 22, 2023
StartActual
Apr 1, 2023
Primary completionActual
Sep 1, 2026was Dec 2025
CompletionActual
Sep 29, 2026was Dec 2026
Last update
Sep 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Sep 30, 2026
Primary completion
Dec 31, 2025→Sep 1, 2026 (actual)
Sep 30, 2026
Study completion
Dec 31, 2026→Sep 29, 2026 (actual)
Sep 30, 2026
Show all 1 update
  1. Sep 30, 2026
    Recruiting→Completed
    Primary completion Dec 31, 2025→Sep 1, 2026 (now actual)
    Study completion Dec 31, 2026→Sep 29, 2026 (now actual)
    + 3 other changes: verification date, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05779605
Lead sponsor
Brno University Hospital
Responsible party
Ladislav Batalik (Principal Investigator, Brno University Hospital) — Principal investigator
First posted
Mar 22, 2023
Start date
Apr 1, 2023
Primary completion
Sep 1, 2026
Completion
Sep 29, 2026
Last update
Sep 30, 2026

Study contacts

Ladislav Batalik
principal investigator · Department of Rehabilitation, University Hospital Brno, Czech Republic

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion